Clinical manufacturing built on development knowledge. Because manufacturing teams are engaged throughout development activities, process knowledge is retained as programs transition into GMP operations. This integrated approach supports efficient technology transfer, process reproducibility, and clinical supply readiness.
Our GMP manufacturing capabilities are part of an integrated Cell Therapy CDMO platform that brings together process development, manufacturing, and quality expertise to support successful clinical translation.
Manufacturing Expertise Across Cell Therapy Modalities
Our GMP manufacturing capabilities combine manufacturing know-how with process understanding established during development. Close collaboration between development and manufacturing teams supports efficient technology transfer, process reproducibility, and clinical supply readiness.
- Autologous, allogeneic and iPSC-based manufacturing
- Closed-system processing and handling
- Clinical batch manufacturing
- Tox-batch and clinical supply production
- Seamless transfer of process knowledge into GMP manufacturing
Manufacturing Designed for Program Growth
Advanced cell therapies require manufacturing strategies that support both current clinical needs and future development milestones. By considering manufacturability and scalability early, we help prepare programs for progression beyond initial clinical supply.
- Processes developed with future scalability in mind
- Focus on robustness, reproducibility and operational efficiency
- Manufacturing strategies aligned with evolving program requirements
- Early consideration of future manufacturing needs
Explore Our Science
- Whitepaper: A Guide to Cell Therapy Technology Transfer >
- Poster: Turning Development Insights into GMP-Ready Processes >
